Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
24 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cryptococcosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cryptococcosis - Pipeline Review, H2 2014', provides an overview of the Cryptococcosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cryptococcosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cryptococcosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cryptococcosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cryptococcosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cryptococcosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cryptococcosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cryptococcosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cryptococcosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Cryptococcosis Overview 5 Therapeutics Development 6 Pipeline Products for Cryptococcosis - Overview 6 Pipeline Products for Cryptococcosis - Comparative Analysis 7 Cryptococcosis - Therapeutics under Investigation by Universities/Institutes 8 Cryptococcosis - Pipeline Products Glance 9 Early Stage Products 9 Cryptococcosis - Products under Investigation by Universities/Institutes 10 Cryptococcosis - Therapeutics Assessment 11 Assessment by Monotherapy Products 11 Assessment by Target 12 Assessment by Mechanism of Action 13 Assessment by Molecule Type 14 Drug Profiles 15 fluorcombstatin - Drug Profile 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Small Molecule for Candidiasis and Cryptococcosis - Drug Profile 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecule for Cryptococcosis and Candidiasis - Drug Profile 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Small Molecule for Fungal Infections - Drug Profile 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Small Molecule for Infectious Diseases - Drug Profile 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Small Molecules for Cryptococcosis - Drug Profile 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Spongistatin-1 - Drug Profile 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Cryptococcosis - Dormant Projects 22 Appendix 23 Methodology 23 Coverage 23 Secondary Research 23 Primary Research 23 Expert Panel Validation 23 Contact Us 24 Disclaimer 24
List of Tables Number of Products under Development for Cryptococcosis, H2 2014 6 Number of Products under Development for Cryptococcosis - Comparative Analysis, H2 2014 7 Number of Products under Investigation by Universities/Institutes, H2 2014 8 Comparative Analysis by Early Stage Development, H2 2014 9 Products under Investigation by Universities/Institutes, H2 2014 10 Assessment by Monotherapy Products, H2 2014 11 Number of Products by Stage and Target, H2 2014 12 Number of Products by Stage and Mechanism of Action, H2 2014 13 Number of Products by Stage and Molecule Type, H2 2014 14 Cryptococcosis - Dormant Projects, H2 2014 22
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.